Regenerx Biopharmaceuticals, Inc. (NYSE Amex:RGN) announced today an article entitled "Experimental drug promotes healing in patients with non-healing corneal ulcers," was published in Ophthalmology Times, Vol. 34, No. 6, Mar 2009. The article describes the data generated by Dr. Steven Dunn, a corneal specialist in Detroit, Michigan, in patients with neurotrophic keratitis caused primarily by the herpes zoster virus and previously reported by the Company. The article may be accessed by pasting the following web address into your web browser.

About RegeneRx Biopharmaceuticals, Inc.

RegeneRx is focused on the discovery and development of novel peptides to accelerate tissue and organ repair. Currently, RegeneRx is developing three product candidates, RGN-137, RGN-259 and RGN-352 for dermal, ophthalmic, and cardiovascular tissue repair, respectively. RegeneRx is also developing RGN-457 for use in pulmonary indications such as cystic fibrosis. These product candidates are based on Tβ4, a synthetic copy of a 43-amino acid, naturally occurring peptide, in part, under an exclusive world-wide license from the National Institutes of Health. RegeneRx holds over 60 world-wide patents and patent applications related to novel peptides.

RegeneRx Technology Background

Tβ4 is a synthetic version of a naturally occurring peptide present in virtually all human cells. It is a first-in-class multi-faceted molecule that promotes endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition, and down-regulates inflammation…